logo BDSP

Base documentaire


  1. Economic impact of feeding a phenylalanine-restricted diet to adults with previously untreated phenylketonuria.

    Article - En anglais

    The aim of the present study was to estimate the direct healthcare cost of managing adults with previously untreated phenylketonuria (PKU) for one year before any dietary restrictions and for the first year after a phenylalanine- (PHE-) restricted diet was introduced.

    The resource use and corresponding costs were estimated from medical records and interviews with health care professionals experienced in caring for adults with previously untreated PKU.

    The mean annual cost of caring for a client being fed an unrestricted diet was estimated to be £83 996.

    In the first year after introducing a PHE-restricted diet, the mean annual cost was reduced by £20 647 to £63 348 as a result of a reduction in nursing time, hospitalizations, outpatient clinic visits and medications.

    However, the economic benefit of the diet depended on whether the clients were previously high or low users of nursing care.

    Nursing time was the key cost-driver, accounting for 79% of the cost of managing high users and 31% of the management cost for low users.

    In contrast, the acquisition cost of a PHE-restricted diet accounted for up to 6% of the cost for managing high users and 15% of the management cost for low users.

    Sensitivity analyses showed that introducing a PHE-restricted diet reduces the annual cost of care, provided that annual nursing time was reduced by more than 8% or more than 5% of clients respond to the diet. (...)

    Mots-clés Pascal : Phénylcétonurie, Traitement, Régime alimentaire restrictif, Phénylalanine, Coût financement, Royaume Uni, Europe, Homme, Métabolisme pathologie, Aminoacidopathie, Système nerveux pathologie, Maladie héréditaire, Enzymopathie

    Mots-clés Pascal anglais : Phenylketonuria, Treatment, Restricted diet, Phenylalanine, Financing cost, United Kingdom, Europe, Human, Metabolic diseases, Aminoacid disorder, Nervous system diseases, Genetic disease, Enzymopathy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0203354

    Code Inist : 002B30A03A. Création : 16/11/1999.